Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
Sponsor: Novartis Pharmaceuticals
A PHASE2 clinical study on Ameloblastoma and BRAF Gene Mutation, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 14 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Feb 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 9 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE2
Phase: NA → PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Not Yet Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .